• Daiichi Sankyo Co., Ltd.

  • Virtual Morning Symposium – Denosumab, anti-RANKL antibody, for the treatment of joint destruction in RA. − From DRIVE & DESIRABLE studies
    Sunday 25 October – 11:30am – 12:45pm

    Check out the morning symposium!